(Q51357360)

4 April 2018

title

The incretin hormones: from scientific discovery to practical therapeutics. (English)

1 reference

4 April 2018

author name string

S Mudaliar

series ordinal

1

1 reference

4 April 2018

R R Henry

series ordinal

2

1 reference

4 April 2018

publication date

4 May 2012

1 reference

4 April 2018

published in

Diabetologia

1 reference

4 April 2018

volume

55

1 reference

4 April 2018

issue

7

1 reference

4 April 2018

page(s)

1865-1868

1 reference

4 April 2018

Glucagon-like peptide-1 7-36: a physiological incretin in man.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

Incretin-based therapies in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

The safety of incretin-based therapies--review of the scientific evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2561-X

Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22555471

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22555471

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00125-012-2561-X

1 reference

4 April 2018

1 reference

4 April 2018